Search

Your search keyword '"D'Angelo, Sandra P"' showing total 506 results
Start Over Author "D'Angelo, Sandra P"
506 results on '"D'Angelo, Sandra P"'

151. A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).

Author

D'Angelo, Sandra P., primary, Druta, Mihaela, additional, Demetri, George D., additional, Liebner, David A., additional, Schuetze, Scott, additional, Singh, Arun S., additional, Somaiah, Neeta, additional, Van Tine, Brian Andrew, additional, Wilky, Breelyn A., additional, Chagin, Karen, additional, Pulham, Tim, additional, Iyengar, Malini, additional, Norry, Elliot, additional, Bartlett-Pandite, Arundathy N., additional, and Amado, Rafael G., additional

Published
2017
Full Text
View/download PDF

152. A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).

Author

Kelly, Ciara Marie, primary, Shoushtari, Alexander Noor, additional, Qin, Li-Xuan, additional, D'Angelo, Sandra P., additional, Dickson, Mark Andrew, additional, Gounder, Mrinal M., additional, Keohan, Mary Louise, additional, Sjoberg, Ana, additional, Mcfadyen, Chloe, additional, Hwang, Sinchun, additional, Heinemann, M.H., additional, Francis, Jasmine, additional, Singer, Samuel, additional, DeMatteo, Ronald P., additional, Antonescu, Cristina R., additional, Chi, Ping, additional, and Tap, William D., additional

Published
2017
Full Text
View/download PDF

153. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.

Author

D'Angelo, Sandra P., primary, Russell, Jeffrey, additional, Hassel, Jessica Cecile, additional, Lebbe, Celeste, additional, Chmielowski, Bartosz, additional, Rabinowits, Guilherme, additional, Terheyden, Patrick, additional, Brownell, Isaac, additional, Zwiener, Isabella, additional, Bajars, Marcis, additional, Hennessy, Meliessa, additional, and Kaufman, Howard, additional

Published
2017
Full Text
View/download PDF

154. Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).

Author

Mackall, Crystal, primary, Tap, William D., additional, Glod, John, additional, Druta, Mihaela, additional, Chow, Warren Allen, additional, Araujo, Dejka M., additional, Grupp, Stephan A., additional, Van Tine, Brian Andrew, additional, Chagin, Karen, additional, Van Winkle, Erin, additional, Kari, Gabor, additional, Trivedi, Trupti, additional, Norry, Elliot, additional, Holdich, Tom, additional, Bartlett-Pandite, Arundathy N., additional, Amado, Rafael G., additional, and D'Angelo, Sandra P., additional

Published
2017
Full Text
View/download PDF

156. Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.

Author

Gounder, Mrinal M., primary, Ali, Siraj Mahamed, additional, Robinson, Victoria, additional, Bailey, Mark, additional, Ferraro, Richard, additional, Patel, Nirali M, additional, Krishnan, Anita, additional, Millis, Sherri Z., additional, Dickson, Mark Andrew, additional, D'Angelo, Sandra P., additional, Keohan, Mary Louise, additional, Miller, Vincent A., additional, Schwartz, Gary K., additional, Maki, Robert G., additional, and Tap, William D., additional

Published
2017
Full Text
View/download PDF

158. Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.

Author

Burgess, Melissa Amber, primary, Roszik, Jason, additional, Van Tine, Brian Andrew, additional, Hu, James, additional, Schuetze, Scott, additional, D'Angelo, Sandra P., additional, Attia, Steven, additional, Priebat, Dennis A., additional, Okuno, Scott H., additional, Riedel, Richard F., additional, Davis, Lara Emily, additional, Movva, Sujana, additional, Reed, Damon R., additional, Baker, Laurence H., additional, Reinke, Denise K., additional, Maki, Robert G., additional, Patel, Shreyaskumar, additional, Tawbi, Hussein Abdul-Hassan, additional, and Butterfield, Lisa Helene, additional

Published
2017
Full Text
View/download PDF

159. Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.

Author

Kaufman, Howard L., primary, Russell, Jeffrey, additional, Hamid, Omid, additional, Bhatia, Shailender, additional, Terheyden, Patrick, additional, D'Angelo, Sandra P., additional, Shih, Kent C., additional, Lebbe, Celeste, additional, Linette, Gerald P, additional, Milella, Michele, additional, Brownell, Isaac, additional, Lewis, Karl D., additional, Lorch, Jochen H., additional, von Heydebreck, Anja, additional, Mahnke, Lisa, additional, and Nghiem, Paul, additional

Published
2017
Full Text
View/download PDF

160. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

Author

D’Angelo, Sandra P., primary, Larkin, James, additional, Sosman, Jeffrey A., additional, Lebbé, Celeste, additional, Brady, Benjamin, additional, Neyns, Bart, additional, Schmidt, Henrik, additional, Hassel, Jessica C., additional, Hodi, F. Stephen, additional, Lorigan, Paul, additional, Savage, Kerry J., additional, Miller, Wilson H., additional, Mohr, Peter, additional, Marquez-Rodas, Ivan, additional, Charles, Julie, additional, Kaatz, Martin, additional, Sznol, Mario, additional, Weber, Jeffrey S., additional, Shoushtari, Alexander N., additional, Ruisi, Mary, additional, Jiang, Joel, additional, and Wolchok, Jedd D., additional

Published
2017
Full Text
View/download PDF

161. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

Author

D'Angelo, Sandra P., Hunger, Matthias, Brohl, Andrew S., Nghiem, Paul, Bhatia, Shailender, Hamid, Omid, Mehnert, Janice M., Terheyden, Patrick, Shih, Kent C., Brownell, Isaac, Lebbé, Céleste, Lewis, Karl D., Linette, Gerald P., Milella, Michele, Schlichting, Michael, Hennessy, Meliessa H., and Bharmal, Murtuza

Subjects
*MERKEL cell carcinoma
Abstract

Background: Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored the association between objective response (OR) and OS in patients with chemotherapy-refractory metastatic Merkel cell carcinoma who received avelumab (anti-PD-L1). Methods: Eighty-eight patients enrolled in JAVELIN Merkel 200 (part A; NCT02155647) received i.v. avelumab 10 mg/kg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal. Using conditional landmark analyses, we compared OS in patients with and without confirmed OR (RECIST v1.1). We applied a Cox model that included OR as a time-varying covariate and adjusted for age, visceral disease, and number of previous therapies. Results: Twenty-nine patients had confirmed OR; 20 by study week 7 and 7 more between study weeks 7 and 13. Survival probabilities 18 months after treatment initiation were 90% [95% confidence interval (CI) 65.6–97.4] in patients with OR at week 7 and 26.2% (95% CI 15.7–37.8) in patients without OR but who were alive at week 7. Median OS was not reached in patients with OR and was 8.8 months (95% CI 6.4–12.9) in patients without. Similar results were observed for the week 13 landmark. The adjusted Cox model showed OR was associated with a 95% risk reduction of death [hazard ratio 0.052 (95% CI 0.018–0.152)] compared with a nonresponse. Conclusions: Patients with OR by 7 or 13 weeks had significantly longer OS than patients without, confirming that early OR is an endpoint of major importance. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

162. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.

Author

Kelly, Ciara M., Shoushtari, Alexander N., Qin, Li-Xuan, D'Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary Louise, Mcfadyen, Chloe, Sjoberg, Ana, Singer, Samuel, DeMatteo, Ronald P., Hwang, Sinchun, Heinemann, M. H., Francis, Jasmine H., Antonescu, Cristina R., Chi, Ping, and Tap, William D.

Subjects
ANTINEOPLASTIC agents, CANCER patients, CLINICAL trials, CONFIDENCE intervals, DRUG resistance in cancer cells, GASTROINTESTINAL tumors, IMATINIB, PROTEIN-tyrosine kinase inhibitors, DESCRIPTIVE statistics
Abstract

Summary: Background Preclinical studies suggest that imatinib resistance in gastrointestinal stromal tumor (GIST) can be mediated by MAP-kinase activation via fibroblast growth factor (FGF) signaling. In FGF stimulated GIST cell lines, BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib, was cytotoxic and superior to imatinib therapy alone. In FGF-dependent GIST, the combination of BGJ398 and imatinib may provide a mechanism to overcome imatinib resistance. Methods This phase Ib study of BGJ398 and imatinib was performed in patients with imatinib refractory advanced GIST. A standard 3 + 3 dosing schema was utilized to determine the recommended phase II dose (RP2D). Two treatment schedules were evaluated incorporating imatinib 400 mg daily in combination with (A) BGJ398 daily 3 weeks on, 1 week off or (B) BGJ398 daily 1 week on, 3 weeks off. Results 16 patients enrolled. The median age was 54 years (range: 44–77), 81% were male, and the median number of lines of prior therapy was 4 [range: 2–6, 13 patients had ≥3 prior therapies]. 12 patients received treatment on schedule A [BGJ398 dose range: 25 – 75 mg]: 2 patients experienced dose limiting toxicities (DLT) (n = 1, myocardial infarction & grade (G)4 CPK elevation; n = 1, G3 ALT elevation) on schedule A (BGJ398 75 mg), significant hyperphosphatemia, an on-target effect, was not observed, implying the maximum tolerated dose was below the therapeutic dose. Following protocol amendment, 4 patients enrolled on schedule B [BGJ398 dose range: 75 − 100 mg]: no DLTs were observed. The most common treatment related adverse events occurring in >15% of patients included CPK elevation (50%), lipase elevation (44%), hyperphosphatemia (24%), anemia (19%), and peripheral edema (19%). Among the 12 evaluable patients, stable disease (SD) was the best response observed in 7 patients by RECIST v1.1 and 9 patients by CHOI. Stable disease ≥ 32 weeks was observed in 3 patients (25%). Median progression free survival was 12.1 weeks (95% CI 4.7–19.5 weeks). Conclusions Toxicity was encountered with the combination therapy of BGJ398 and imatinib. Due to withdrawal of sponsor support the study closed before the RP2D or dosing schedule of the combination therapy was identified. In heavily pre-treated patients, stable disease ≥ 32 weeks was observed in 3 of 12 evaluable patients. Trial Registration: NCT02257541. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

163. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Author

Kaufman, Howard L, primary, Russell, Jeffery, additional, Hamid, Omid, additional, Bhatia, Shailender, additional, Terheyden, Patrick, additional, D'Angelo, Sandra P, additional, Shih, Kent C, additional, Lebbé, Céleste, additional, Linette, Gerald P, additional, Milella, Michele, additional, Brownell, Isaac, additional, Lewis, Karl D, additional, Lorch, Jochen H, additional, Chin, Kevin, additional, Mahnke, Lisa, additional, von Heydebreck, Anja, additional, Cuillerot, Jean-Marie, additional, and Nghiem, Paul, additional

Published
2016
Full Text
View/download PDF

164. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Author

Gounder, Mrinal M., primary, Zer, Alona, additional, Tap, William D., additional, Salah, Samer, additional, Dickson, Mark A., additional, Gupta, Abha A., additional, Keohan, Mary Louise, additional, Loong, Herbert H., additional, D’Angelo, Sandra P., additional, Baker, Stephanie, additional, Condy, Mercedes, additional, Nyquist-Schultz, Kjirsten, additional, Tanner, Lanier, additional, Erinjeri, Joseph P., additional, Jasmine, Francis H., additional, Friedlander, Sharon, additional, Carlson, Robert, additional, Unger, Thaddeus J., additional, Saint-Martin, Jean-Richard, additional, Rashal, Tami, additional, Ellis, Joel, additional, Kauffman, Michael, additional, Shacham, Sharon, additional, Schwartz, Gary K., additional, and Abdul Razak, Albiruni Ryan, additional

Published
2016
Full Text
View/download PDF

166. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib

Author

Dickson, Mark A., primary, Schwartz, Gary K., additional, Keohan, Mary Louise, additional, D’Angelo, Sandra P., additional, Gounder, Mrinal M., additional, Chi, Ping, additional, Antonescu, Cristina R., additional, Landa, Jonathan, additional, Qin, Li-Xuan, additional, Crago, Aimee M., additional, Singer, Samuel, additional, Koff, Andrew, additional, and Tap, William D., additional

Published
2016
Full Text
View/download PDF

167. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.

Author

Kaufman, Howard, primary, Russell, Jeffery Scott, additional, Hamid, Omid, additional, Bhatia, Shailender, additional, Terheyden, Patrick, additional, D'Angelo, Sandra P., additional, Shih, Kent C., additional, Lebbe, Celeste, additional, Linette, Gerald P, additional, Milella, Michele, additional, Brownell, Isaac, additional, Lewis, Karl D., additional, Lorch, Jochen H., additional, Chin, Kevin M., additional, Mahnke, Lisa, additional, von Heydebreck, Anja, additional, Cuillerot, Jean-Marie, additional, and Nghiem, Paul, additional

Published
2016
Full Text
View/download PDF

168. Efficacy of sorafenib in patients with desmoid-type fibromatosis.

Author

Munhoz, Rodrigo Ramella, primary, Lefkowitz, Robert A, additional, Kuk, Deborah, additional, Dickson, Mark Andrew, additional, D'Angelo, Sandra P., additional, Keohan, Mary Louise, additional, Chi, Ping, additional, Crago, Aimee Marie, additional, Maki, Robert G., additional, Schwartz, Gary K., additional, Qin, Li-Xuan, additional, Tap, William D., additional, and Gounder, Mrinal M., additional

Published
2016
Full Text
View/download PDF

169. Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

Author

Mackall, Crystal, primary, D'Angelo, Sandra P., additional, Grupp, Stephan A., additional, Odunsi, Kunle, additional, Cristea, Mihaela C., additional, Linette, Gerald P., additional, Kluger, Harriet M., additional, Kari, Gabor, additional, Pandite, Lini, additional, Holdich, Tom, additional, Norry, Elliot, additional, Binder-Scholl, Gwendolyn, additional, and Amado, Rafael G., additional

Published
2016
Full Text
View/download PDF

170. Outcomes of systemic therapy for patients with metastatic undifferentiated pleomorphic sarcoma (UPS).

Author

Adrianzen Herrera, Diego Andres, primary, Kuk, Deborah, additional, Keohan, Mary Louise, additional, Dickson, Mark Andrew, additional, D'Angelo, Sandra P., additional, Chi, Ping, additional, Agaram, Narasimhan P, additional, Antonescu, Cristina R., additional, Hameed, M, additional, Tap, William D., additional, Qin, Li-Xuan, additional, and Gounder, Mrinal M., additional

Published
2016
Full Text
View/download PDF

171. Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.

Author

Mackall, Crystal, primary, D'Angelo, Sandra P., additional, Cristea, Mihaela C., additional, Odunsi, Kunle, additional, Norry, Elliot, additional, Pandite, Lini, additional, Holdich, Tom, additional, Kari, Gabor, additional, Ramachandran, Indu R., additional, Ribeiro, Lilliam, additional, Binder-Scholl, Gwendolyn, additional, and Amado, Rafael G., additional

Published
2016
Full Text
View/download PDF

172. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Author

Naidoo, Jarushka, primary, Schindler, Katja, additional, Querfeld, Christiane, additional, Busam, Klaus, additional, Cunningham, Jane, additional, Page, David B., additional, Postow, Michael A., additional, Weinstein, Alyona, additional, Lucas, Anna Skripnik, additional, Ciccolini, Kathryn T., additional, Quigley, Elizabeth A., additional, Lesokhin, Alexander M., additional, Paik, Paul K., additional, Chaft, Jamie E., additional, Segal, Neil H., additional, D'Angelo, Sandra P., additional, Dickson, Mark A., additional, Wolchok, Jedd D., additional, and Lacouture, Mario E., additional

Published
2016
Full Text
View/download PDF

174. Reply to A. Indini et al

Author

Horvat, Troy Z., primary, Adel, Nelly G., additional, Dang, Thu-Oanh, additional, Momtaz, Parisa, additional, Postow, Michael A., additional, Callahan, Margaret K., additional, Carvajal, Richard D., additional, Dickson, Mark A., additional, D’Angelo, Sandra P., additional, Woo, Kaitlin M., additional, Panageas, Katherine S., additional, Wolchok, Jedd D., additional, and Chapman, Paul B., additional

Published
2016
Full Text
View/download PDF

175. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial

Author

Weber, Jeffrey S, D'Angelo, Sandra P, Minor, David, Hodi, F Stephen, Gutzmer, Ralf, Neyns, Bart, Hoeller, Christoph, Khushalani, Nikhil I, Miller, Wilson H, Lao, Christopher D, Linette, Gerald P, Thomas, Luc, Lorigan, Paul, Grossmann, Kenneth F, Hassel, Jessica C, Maio, Michele, Sznol, Mario, Ascierto, Paolo A, Mohr, Peter, Chmielowski, Bartosz, Bryce, Alan, Svane, Inge Marie, Grob, Jean-Jacques, Krackhardt, Angela M, Horak, Christine, Lambert, Alexandre, Yang, Arvin S, Larkin, James, Weber, Jeffrey S, D'Angelo, Sandra P, Minor, David, Hodi, F Stephen, Gutzmer, Ralf, Neyns, Bart, Hoeller, Christoph, Khushalani, Nikhil I, Miller, Wilson H, Lao, Christopher D, Linette, Gerald P, Thomas, Luc, Lorigan, Paul, Grossmann, Kenneth F, Hassel, Jessica C, Maio, Michele, Sznol, Mario, Ascierto, Paolo A, Mohr, Peter, Chmielowski, Bartosz, Bryce, Alan, Svane, Inge Marie, Grob, Jean-Jacques, Krackhardt, Angela M, Horak, Christine, Lambert, Alexandre, Yang, Arvin S, and Larkin, James

Abstract

BACKGROUND: Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma.METHODS: In this randomised, controlled, open-label, phase 3 trial, we recruited patients at 90 sites in 14 countries. Eligible patients were 18 years or older, had unresectable or metastatic melanoma, and progressed after ipilimumab, or ipilimumab and a BRAF inhibitor if they were BRAF(V 600) mutation-positive. Participating investigators randomly assigned (with an interactive voice response system) patients 2:1 to receive an intravenous infusion of nivolumab 3 mg/kg every 2 weeks or ICC (dacarbazine 1000 mg/m(2) every 3 weeks or paclitaxel 175 mg/m(2) combined with carboplatin area under the curve 6 every 3 weeks) until progression or unacceptable toxic effects. We stratified randomisation by BRAF mutation status, tumour expression of PD-L1, and previous best overall response to ipilimumab. We used permuted blocks (block size of six) within each stratum. Primary endpoints were the proportion of patients who had an objective response and overall survival. Treatment was given open-label, but those doing tumour assessments were masked to treatment assignment. We assessed objective responses per-protocol after 120 patients had been treated with nivolumab and had a minimum follow-up of 24 weeks, and safety in all patients who had had at least one dose of treatment. The trial is closed and this is the first interim analysis, reporting the objective response primary endpoint. This study is registered with ClinicalTrials.gov, number NCT01721746.FINDINGS: Between Dec 21, 2012, and Jan 10, 2014, we screened 631 patients, randomly allocating 272 patients to nivolumab and 133 to ICC

Published
2015

176. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Author

Larkin, James, Minor, David, D'Angelo, Sandra, Neyns, Bart, Smylie, Michael, Miller, Wilson H., Gutzmer, Ralf, Linette, Gerald, Chmielowski, Bartosz, Lao, Christopher D., Lorigan, Paul, Grossmann, Kenneth, Hassel, Jessica C., Sznol, Mario, Daud, Adil, Sosman, Jeffrey, Khushalani, Nikhil, Schadendorf, Dirk, Hoeller, Christoph, and Walker, Dana

Published
2018
Full Text
View/download PDF

177. A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

Author

D’Angelo, Sandra P., Hamid, Omid A., Tarhini, Ahmad, Schadendorf, Dirk, Chmielowski, Bartosz, Collichio, Frances A., Pavlick, Anna C., Lewis, Karl D., Weil, Susan C., Heyburn, John, Schweizer, Charles, O’Shannessy, Daniel J., and Carvajal, Richard D.

Subjects
THERAPEUTIC use of monoclonal antibodies, BIOMARKERS, CONFIDENCE intervals, CLINICAL drug trials, FATIGUE (Physiology), HEADACHE, MELANOMA, METASTASIS, MONOCLONAL antibodies, NAUSEA, NEOVASCULARIZATION, DISEASE progression, DESCRIPTIVE statistics
Abstract

Objectives Ontuxizumab (MORAB-004) is a first-in-class monoclonal antibody that interferes with endosialin function, which is important in tumor stromal cell function, angiogenesis, and tumor growth. This Phase 2 study evaluated the 24-week progression-free survival (PFS) value, pharmacokinetics, and tolerability of 2 doses of ontuxizumab in patients with metastatic melanoma. Patients and methods Patients with metastatic melanoma and disease progression after receiving at least 1 prior systemic treatment were randomized to receive ontuxizumab (2 or 4 mg/kg) weekly, without dose change, until disease progression. Results Seventy-six patients received at least 1 dose of ontuxizumab (40 received 2 mg/kg, 36 received 4 mg/kg). The primary endpoint, 24-week PFS value, was 11.4% (95% Confidence Interval [CI]: 5.3%–19.9%) for all patients (13.5% for 2 mg/kg and 8.9% for 4 mg/kg). The median PFS for all patients was 8.3 weeks (95% CI: 8.1–12.3 weeks). One patient receiving 4 mg/kg had a partial response, as measured by Response Evaluation Criteria in Solid Tumors v1.1. Twenty-seven of 66 response evaluable patients (40.9%) had stable disease. The median overall survival was 31.0 weeks (95% CI: 28.3–44.0 weeks). The most common adverse events overall were headache (55.3%), fatigue (48.7%), chills (42.1%), and nausea (36.8%), mostly grade 1 or 2. Conclusions Ontuxizumab at both doses was well tolerated. The 24-week PFS value was 11.4% among all ontuxizumab-treated patients. The overall response rate was 3.1% at the 4 mg/kg dose, with clinical benefit achieved in 42.4% of response evaluable patients. Efficacy of single-agent ontuxizumab at these doses in melanoma was low. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

178. Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1Mutations

Author

Zauderer, Marjorie G., Jayakumaran, Gowtham, DuBoff, Mariel, Zhang, Liying, Francis, Jasmine H., Abramson, David H., Cercek, Andrea, Nash, Garrett M., Shoushtari, Alexander, Chapman, Paul, D’Angelo, Sandra, Arnold, Angela G., Siegel, Beth, Fleischut, Megan Harlan, Ni, Andy, Rimner, Andreas, Rusch, Valerie W., Adusumilli, Prasad S., Travis, William, Sauter, Jennifer L., Zehir, Ahmet, Mandelker, Diana, Ladanyi, Marc, and Robson, Mark

Abstract

Inherited mutations are easily detected factors that influence the disease courses and optimal treatment strategies of some cancers. Germline mutations in BRCA1 associated protein 1 (BAP1) are associated with unique disease profiles in mesothelioma, atypical spitz nevi, and uveal melanoma, but the patient characteristics of an unselected population of BAP1carriers identified by an ascertainment prevalence study are unknown.

Published
2019
Full Text
View/download PDF

179. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Author

Samstein, Robert M., Lee, Chung-Han, Shoushtari, Alexander N., Hellmann, Matthew D., Shen, Ronglai, Janjigian, Yelena Y., Barron, David A., Zehir, Ahmet, Jordan, Emmet J., Omuro, Antonio, Kaley, Thomas J., Kendall, Sviatoslav M., Motzer, Robert J., Hakimi, A. Ari, Voss, Martin H., Russo, Paul, Rosenberg, Jonathan, Iyer, Gopa, Bochner, Bernard H., Bajorin, Dean F., Al-Ahmadie, Hikmat A., Chaft, Jamie E., Rudin, Charles M., Riely, Gregory J., Baxi, Shrujal, Ho, Alan L., Wong, Richard J., Pfister, David G., Wolchok, Jedd D., Barker, Christopher A., Gutin, Philip H., Brennan, Cameron W., Tabar, Viviane, Mellinghoff, Ingo K., DeAngelis, Lisa M., Ariyan, Charlotte E., Lee, Nancy, Tap, William D., Gounder, Mrinal M., D’Angelo, Sandra P., Saltz, Leonard, Stadler, Zsofia K., Scher, Howard I., Baselga, Jose, Razavi, Pedram, Klebanoff, Christopher A., Yaeger, Rona, Segal, Neil H., Ku, Geoffrey Y., DeMatteo, Ronald P., Ladanyi, Marc, Rizvi, Naiyer A., Berger, Michael F., Riaz, Nadeem, Solit, David B., Chan, Timothy A., and Morris, Luc G. T.

Abstract

Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) may predict clinical response to ICI. To examine this association more broadly, we analyzed the clinical and genomic data of 1,662 advanced cancer patients treated with ICI, and 5,371 non-ICI-treated patients, whose tumors underwent targeted next-generation sequencing (MSK-IMPACT). Among all patients, higher somatic TMB (highest 20% in each histology) was associated with better overall survival. For most cancer histologies, an association between higher TMB and improved survival was observed. The TMB cutpoints associated with improved survival varied markedly between cancer types. These data indicate that TMB is associated with improved survival in patients receiving ICI across a wide variety of cancer types, but that there may not be one universal definition of high TMB.

Published
2019
Full Text
View/download PDF

180. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.

Author

Kasago, Israel S., Chatila, Walid K., Lezcano, Cecilia M., Febres-Aldana, Christopher A., Schultz, Nikolaus, Vanderbilt, Chad, Dogan, Snjezana, Bartlett, Edmund K., D'Angelo, Sandra P., Tap, William D., Singer, Samuel, Ladanyi, Marc, Shoushtari, Alexander N., Busam, Klaus J., and Hameed, Meera

Published
2023
Full Text
View/download PDF

181. A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.

Author

D'Angelo, Sandra P., Rosenbaum, Evan, Gularte Mérida, Rodrigo, Dickson, Mark Andrew, Keohan, Mary Louise, Gounder, Mrinal M., Chi, Ping, Movva, Sujana, Kelly, Ciara Marie, Avutu, Viswatej, Chan, Jason Earl, Cho, Jae, Biniakewitz, Matthew, Cho, Grace, Erinjeri, Joseph Patrick, Lefkowitz, Robert A, Antonescu, Cristina R., Qin, Li-Xuan, Singer, Samuel, and Tap, William D.

Published
2023
Full Text
View/download PDF

183. The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.

Author

D'Angelo, Sandra P., Ganjoo, Kristen N., Blay, Jean-Yves, Valverde, Claudia, Araujo, Dejka M., Abdul Razak, Albiruni Ryan, Le Cesne, Axel, Schuetze, Scott, Wagner, Michael J, Attia, Steven, Forcade, Edouard, Druta, Mihaela, Pollack, Seth, Bai, Jane, Lunt, Colin, Sun, Amy, Yule, Murray, McAlpine, Cheryl, Williams, Dennis, and Van Tine, Brian Andrew

Published
2023
Full Text
View/download PDF

185. A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.

Author

Kelly, Ciara Marie, Avutu, Viswatej, Chi, Ping, Dickson, Mark Andrew, Gounder, Mrinal M., Keohan, Mary Louise, Movva, Sujana, Rosenbaum, Evan, Cordover, Emma, Ariyan, Charlotte Eielson, Bartlett, Edmund, Crago, Aimee Marie, Singer, Samuel, Antonescu, Cristina R., Hwang, Sinchun, Erinjeri, Joseph Patrick, Seier, Kenneth, Qin, Li-Xuan, Tap, William D., and D'Angelo, Sandra P.

Published
2023
Full Text
View/download PDF

186. The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.

Author

Van Tine, Brian Andrew, Ganjoo, Kristen N., Blay, Jean-Yves, Valverde, Claudia, Araujo, Dejka M., Abdul Razak, Albiruni Ryan, Le Cesne, Axel, Schuetze, Scott, Wagner, Michael J, Attia, Steven, Forcade, Edouard, Druta, Mihaela, Pollack, Seth, Bai, Jane, Bayer, Paige, Van Winkle, Erin, Norry, Elliot, McAlpine, Cheryl, Williams, Dennis, and D'Angelo, Sandra P.

Published
2023
Full Text
View/download PDF

187. Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS).

Author

Rosenbaum, Evan, Qin, Li-Xuan, Dickson, Mark Andrew, Keohan, Mary Louise, Gounder, Mrinal M., Chi, Ping, Movva, Sujana, Kelly, Ciara Marie, Avutu, Viswatej, Chan, Jason Earl, Martindale, Moriah, Adamson, Travis, Clark, Camron, Desir, Rhoena, Biniakewitz, Matthew, Cho, Grace, Erinjeri, Joseph Patrick, Lefkowitz, Robert A, Tap, William D., and D'Angelo, Sandra P.

Published
2023
Full Text
View/download PDF

188. A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

Author

Movva, Sujana, Avutu, Viswatej, Chi, Ping, Dickson, Mark Andrew, Gounder, Mrinal M., Kelly, Ciara Marie, Keohan, Mary Louise, Meyers, Paul A., Cohen, Seth M., Hensley, Martee Leigh, Konner, Jason A., Schram, Alison M., Lefkowitz, Robert A, Erinjeri, Joseph Patrick, Qin, Li-Xuan, Salcito, Tiffany, Seier, Kenneth, Tap, William D., and D'Angelo, Sandra P.

Published
2023
Full Text
View/download PDF

189. A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).

Author

Grilley-Olson, Juneko E., Allred, Jacob B., Schuetze, Scott, Davis, Elizabeth J., Wagner, Michael J, Poklepovic, Andrew Stewart, Waechter, Blake, Riedel, Richard F., WELLIVER, Meng Xu, Berg, Stephanie A., George, Suzanne, Robinson, Steven Ian, Googe, Paul B., D'Angelo, Sandra P., and Schwartz, Gary K.

Published
2023
Full Text
View/download PDF

190. 小细胞肺癌的的分子发病机制

Author

D'ANGELO, Sandra P. and Catherine PIETANZA, M.

Subjects
Gene Expression Regulation, Neoplastic, 期刊博览, Lung Neoplasms, Animals, Humans, Small Cell Lung Carcinoma, Signal Transduction
Published
2010

191. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas

Author

Gounder, Mrinal, primary, Desai, Ved, additional, Kuk, Deborah, additional, Agaram, Narasimhan, additional, Arcila, Maria, additional, Durham, Benjamin, additional, Keohan, Mary L., additional, Dickson, Mark A., additional, D’Angelo, Sandra P., additional, Shukla, Neerav, additional, Moskowitz, Craig, additional, Noy, Ariela, additional, Maki, Robert G., additional, Herrera, Diego Adrianzen, additional, Sanchez, Armando, additional, Krishnan, Anita, additional, Pourmoussa, Andrew, additional, Qin, Li-Xuan, additional, and Tap, William D., additional

Published
2015
Full Text
View/download PDF

192. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

Author

Munhoz, Rodrigo R., primary, D'Angelo, Sandra P., additional, Gounder, Mrinal M., additional, Keohan, Mary L., additional, Chi, Ping, additional, Carvajal, Richard D., additional, Singer, Samuel, additional, Crago, Aimee M., additional, Landa, Jonathan, additional, Healey, John H., additional, Qin, Li-Xuan, additional, Hameed, Meera, additional, Ezeoke, Marietta O., additional, Singh, Arun S., additional, Agulnik, Mark, additional, Chmielowski, Bartosz, additional, Luke, Jason J., additional, Van Tine, Brian A., additional, Schwartz, Gary K., additional, Tap, William D., additional, and Dickson, Mark A., additional

Published
2015
Full Text
View/download PDF

193. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Author

Horvat, Troy Z., primary, Adel, Nelly G., additional, Dang, Thu-Oanh, additional, Momtaz, Parisa, additional, Postow, Michael A., additional, Callahan, Margaret K., additional, Carvajal, Richard D., additional, Dickson, Mark A., additional, D'Angelo, Sandra P., additional, Woo, Kaitlin M., additional, Panageas, Katherine S., additional, Wolchok, Jedd D., additional, and Chapman, Paul B., additional

Published
2015
Full Text
View/download PDF

194. Abstract 4707: Genetically engineered NY-ESO-1-specific T cells in HLA-A2+ patients with synovial sarcoma

Author

Merchant, Melinda S., primary, D'Angelo, Sandra P., additional, Zhang, Hua, additional, Bernstein, Donna, additional, Binder-Scholl, Gwen, additional, Holdich, Tom, additional, Melchiori, Luca, additional, Williams, Dan, additional, Fortin, Marylene, additional, Peretz, Yoav, additional, Howe, Jason, additional, Mehler, Michael, additional, Hug, Bruce A., additional, Wright, Matthew, additional, Grupp, Stephen, additional, Meyers, Paul A., additional, Tap, William, additional, Jakobsen, Bent, additional, and Mackall, Crystal L., additional

Published
2015
Full Text
View/download PDF

195. SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.

Author

Burgess, Melissa Amber, primary, Crowley, John, additional, Reinke, Denise K., additional, Riedel, Richard F., additional, George, Suzanne, additional, Movva, Sujana, additional, Van Tine, Brian Andrew, additional, Davis, Lara Emily, additional, Schuetze, Scott, additional, Hu, James, additional, Attia, Steven, additional, Priebat, Dennis A., additional, Reed, Damon R., additional, D'Angelo, Sandra P., additional, Okuno, Scott H., additional, Maki, Robert G., additional, Patel, Shreyaskumar, additional, Baker, Laurence H., additional, and Tawbi, Hussein Abdul-Hassan, additional

Published
2015
Full Text
View/download PDF

196. A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis.

Author

Gounder, Mrinal M., primary, Zer, Alona, additional, Tap, William D., additional, Gupta, Abha A., additional, Keohan, Mary Louise, additional, Dickson, Mark Andrew, additional, D'Angelo, Sandra P., additional, Chi, Ping, additional, Tanner, Lanier R., additional, Konen, Theresa, additional, Rashal, Tami, additional, McCauley, Dilara, additional, Saint-Martin, Jean-Richard, additional, Carlson, Robert, additional, Marshall, Tracey, additional, Shacham, Sharon, additional, Mirza, Mansoor Raza, additional, Kauffman, Michael, additional, Schwartz, Gary, additional, and Razak, Albiruni R. A., additional

Published
2015
Full Text
View/download PDF

198. Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.

Author

Gomez-Roca, Carlos Alberto, primary, Cassier, Philippe Alexandre, additional, Italiano, Antoine, additional, Cannarile, Michael, additional, Ries, Carola, additional, Brillouet, Anne, additional, Mueller, Claudia, additional, Jegg, Anna-Maria, additional, Meneses-Lorente, Georgina, additional, Baehner, Monika, additional, Abiraj, Keelara, additional, Loirat, Delphine, additional, Toulmonde, Maud, additional, D'Angelo, Sandra P., additional, Weber, Kristy, additional, Campone, Mario, additional, Ruettinger, Dominik, additional, Blay, Jean-Yves, additional, Delord, Jean-Pierre, additional, and Le Tourneau, Christophe, additional

Published
2015
Full Text
View/download PDF

199. Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.

Author

Merchant, Melinda S., primary, Cristea, Mihaela C., additional, Stadtmauer, Edward A., additional, Tap, William D., additional, D'Angelo, Sandra P., additional, Grupp, Stephan A., additional, Holdich, Tom, additional, Binder-Scholl, Gwendolyn, additional, Jakobsen, Bent K, additional, Odunsi, Kunle, additional, Rapoport, Aaron, additional, and Mackall, Crystal, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results